ESR1 and uterine cancer: Coupling to ER-ß does not exert transcriptional activity and demonstrates an antagonistic effect on ER-α signaling [53,54]. These therapies are particularly useful in treating and preventing estrogen-dependent conditions where their receptor selectivity can be leveraged in patients at increased risk of breast or uterine cancer, such as those with a positive family history.